Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MarketLine (a Datamonitor Company)
$50.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alexion Pharmaceuticals Inc raises FY 2014 guidance


Monday, 10 Mar 2014 06:30am EDT 

Alexion Pharmaceuticals Inc:Raises FY 2014 net revenue guidance from the prior range of $2.000 to $2.020 bln to the higher range of $2.150 to $2.170 bln, which includes the $88 million in net product sales related to years prior to 2014 to be recorded in Q1 2014.Raises FY 2014 non-GAAP EPS guidance from the prior range of $3.70 to $3.80 to the higher range of $4.37 to $4.47, which includes 37 cents attributable to net product sales related to years prior to 2014 to be recorded in Q1 2014.FY 2014 revenue of $2.03 bln and EPS of $3.89 - Thomson Reuters I/B/E/S. 

Company Quote

167.97
4.6 +2.82%
4:00pm EDT